This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| IMAT | |
|---|---|
| Name | IMAT |
| Type | Small-molecule inhibitor |
| Routes of administration | Oral |
| Legal status | Prescription-only |
| Metabolism | Hepatic |
| Elimination | Renal and fecal |
IMAT is a targeted small-molecule inhibitor used in oncology and hematology. It selectively modulates signal transduction pathways implicated in malignancies and hematopoietic disorders, and has been evaluated across randomized trials, cohort studies, and regulatory reviews. Major academic centers, pharmaceutical companies, and international regulatory agencies have contributed to the clinical development, approval, and post-marketing surveillance of IMAT.
IMAT acts on specific tyrosine kinases and downstream effectors implicated in cell proliferation and survival. Key clinical investigation sites include Mayo Clinic, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Johns Hopkins Hospital, and Cleveland Clinic. Pivotal trials were coordinated by consortia such as European Organisation for Research and Treatment of Cancer, European Medicines Agency, National Institutes of Health, and collaborative groups including Children's Oncology Group and SWOG. Influential principal investigators have included researchers affiliated with Harvard Medical School, University of Oxford, University of Cambridge, Stanford University School of Medicine, and University of California, San Francisco.
Early preclinical work emerged from academic laboratories at Massachusetts Institute of Technology and University of Pennsylvania that explored kinase inhibition models, building on foundational studies from Nobel Prize in Physiology or Medicine laureates in signal transduction. Initial lead optimization involved partnerships between biotech firms and major pharmaceutical companies such as Pfizer, Novartis, Roche, and GlaxoSmithKline. Phase I studies were conducted at centers including MD Anderson Cancer Center and Guy's and St Thomas' NHS Foundation Trust, followed by Phase II and III trials overseen by cooperative groups like EORTC and regulatory submissions to agencies including Food and Drug Administration and European Medicines Agency. Post-approval, real-world evidence was gathered through registries maintained by institutions such as National Cancer Institute and national health services like National Health Service (England), and outcomes were reported in journals edited by organizations such as American Society of Clinical Oncology and European Society for Medical Oncology.
Chemically, IMAT is a heterocyclic small molecule engineered to bind the ATP-binding pocket of target kinases. Structural biology studies used crystallography performed at facilities including European Synchrotron Radiation Facility, Brookhaven National Laboratory, and Diamond Light Source. Mechanistic work referenced pathway mapping from laboratories at Salk Institute and Cold Spring Harbor Laboratory that connect target inhibition to modulation of pathways described in studies from The Rockefeller University and Karolinska Institutet. Preclinical pharmacology included experiments at Institut Pasteur, Max Planck Society institutes, and university cores at Columbia University Irving Medical Center.
IMAT has been indicated for specific malignancies and hematologic conditions based on trial populations enrolled at centers like St. Jude Children's Research Hospital, Royal Marsden Hospital, Mount Sinai Hospital (New York), and Karolinska University Hospital. Indications evaluated include subtypes that were defined in trials using diagnostic criteria from organizations such as World Health Organization classifications and staging systems aligned with American Joint Committee on Cancer guidelines. Treatment regimens and combination strategies were studied in trials coordinated by groups including Alliance for Clinical Trials in Oncology and Cancer Research UK.
Randomized controlled trials comparing IMAT to standard therapies involved endpoints commonly adopted by groups such as European Medicines Agency and Food and Drug Administration, including progression-free survival and overall survival. Major outcome reports were published in journals affiliated with American Society of Hematology, American Society of Clinical Oncology, and The Lancet Oncology. Survival benefits, response rates, and patient-reported outcomes were monitored in multicenter studies spanning institutions like Vanderbilt University Medical Center, University of Toronto, and University College London Hospital.
Safety profiles were characterized in investigator-initiated trials and pharmacovigilance databases operated by national agencies such as Medicines and Healthcare products Regulatory Agency and European Medicines Agency. Common and serious adverse events were managed according to guidelines from professional bodies including American Society of Clinical Oncology, European Society for Medical Oncology, and specialty societies such as International Society of Hematology. Post-market surveillance involved reporting systems such as those maintained by Food and Drug Administration and national pharmacovigilance centers in countries with registries like Australia Therapeutic Goods Administration.
Regulatory decisions for IMAT were made by agencies such as Food and Drug Administration, European Medicines Agency, Pharmaceuticals and Medical Devices Agency, Health Canada, and national authorities within the European Union. Availability varies by country and is influenced by reimbursement decisions from payers and health technology assessment bodies including National Institute for Health and Care Excellence and Institute for Clinical and Economic Review. Distribution and manufacturing partnerships have involved multinational pharmaceutical networks and contract manufacturers working with academic licensors and biotechnology firms.
Category:Anti-cancer drugs